The Relationship Between Dopamine and Mel... - Cure Parkinson's
The Relationship Between Dopamine and Melatonin. Bronowski Institute
very informative; thanks for sharing . What light are they referring to?
chartist
A historical justification for and retrospective analysis of the systematic application of light therapy in Parkinson’s disease 2012
Rev. Neurosci., Vol. 23(2): 199–226, 2012 • Copyright © by Walter de Gruyter • Berlin • Boston. DOI 10.1515/revneuro-2011-0072
A historical justification for and retrospective analysis of the systematic application of light therapy in Parkinson’s disease
Gregory L. Willis*, Cleo Moore
and Stuart M. Armstrong
The Bronowski Clinic , The Bronowski Institute of
Behavioural Neuroscience, Coliban Medical Centre,
19 Jennings Street, Kyneton, Victoria 3444 , Australia
* Corresponding author
e-mail: director@bronowski.org
sci-hub.ru/10.1515/revneuro...
A historical justification for and retrospective analysis of the systematic application of light therapy in Parkinson’s disease 2012 sci-hub.ru/10.1515/revneuro...
Rev. Neurosci., Vol. 23(2): 199–226, 2012 • Copyright © by Walter de Gruyter • Berlin • Boston. DOI 10.1515/revneuro-2011-0072
A historical justification for and retrospective analysis of the systematic application of light therapy in Parkinson’s disease
Gregory L. Willis*, Cleo Moore and Stuart M. Armstrong
The Bronowski Clinic , The Bronowski Institute of
Behavioural Neuroscience, Coliban Medical Centre,
19 Jennings Street, Kyneton, Victoria 3444 , Australia
* Corresponding author e-mail: director@bronowski.org
(I have edited this and moved things around)
Open-label study on 129 PD patients, whereby they were monitored for a period extending for a few months to eight years, was carried out. Primary motor and non-motor symptoms were monitored using an objectified global rating scale and timed motor tests that were assessed at regular intervals for the duration of the study. Thirty-one patients with other neurological disorders (OND) served as controls to determine whether any therapeutic effects seen with light were generalizable across other conditions.
Patients were classified as compliant (COM), semi-compliant (SCOM), or early quit (EQUIT; prematurely discontinued treatment). EQUIT patients showed deterioration, while the COM group improved on most parameters. The SCOM patients were not as good as the COM group. The OND group showed significant improvement in depression and insomnia, but exposure to light did not improve motor function. The total drug burden of PD patients maintained on light was less with fewer side effects than SCOM or EQUIT groups.
Methods:
Light was administered by utilizing a light box containing fluorescent tubes (Apollo BL-6®, Love-Lite®, or equivalent without ultraviolet emission) and placed 1.0 to 1.2 m from the patient at the 1:00 or 11:00 position relative to the sagittal plane of the head.
All patients were maintained in the long term on polychromatic light, with the exception that a blue, green or red filter was placed over the light during a brief pilot study in 12 patients. Since melatonin is secreted primarily at night (Roth et al. , 1962 ; Ralph , 1976 ) light was usually administered for 1 h between the hours of 20:00 and 22:00 and in
most cases this was just prior to retiring and was tied to bedtime.
With PD patients having been described as ‘ phase advanced ’ (Fertlet al. , 1991 ; Bordet et al. , 2003 ) the time of exposure to light would occur during the peak in melatonin secretion hypothesized to occur at 22:00 to 23:00 h. As a general rule of thumb, light was administered at a dose of 4000 – 6000 lux and was continued indefinitely, or until the patient voluntarily opted out of the program.
Results
As shown in Figure 2A, EQUIT patients demonstrated a gradual increase in the severity of bradykinesia after commencing the program, while COM patients demonstrated a large margin of improvement. In SCOM, there was some benefit but it was not as robust as that seen in COM patients.
While there was also improvement in bradykinesia demonstrated in OND patients who received light treatment, the improvement seen was only minor compared to the COM patients.
These results confirm the value of the strategic application of light therapy with controlled doses of DART in PD and warrants further controlled investigation. That the symptomatic improvement continued as long patients remained in the program suggests that exposure to light, under a strict daily regimen, combined with controlled DART, actively slows or arrests the progressive degenerative process underlying PD.
Hi, Does it mean that Parkinson patients should try the SAD lamp in the morning and take melatonin supplements at nights?
Very interesting ! I thank you Thal.
This video is 11 years old. It assumes only pineal melatonin functions. Since then intracellular melatonin has been discovered.
Any suggestions for HWP melatonin exacerabtes his RLS even at low doses.
Not what you're looking for?
You may also like...
Does Melatonin Deplete Dopamine?
Dopamine.
Ozempic effects dopamine?
Another Potential Benefit Of Melatonin for PwP 
Melatonin and tremors 
